There is strong evidence from both epidemiological and basic science research that small, dense subfractions of low-density lipoprotein (LDL) play a key role in atherogenesis.' Small, dense LDL particles are made by a process of neutral lipid exchange, catalysed by cholesteryl ester transfer protein (CETP), followed by delipidation, catalysed by hepatic lipase." The principal determinant of subfraction size is serum triglyceride concentration; the higher the triglyceride concentration, the greater the proportion of small, dense LDL subfractions.
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Research efforts now focus on the development of therapeutic strategies to improve the LDL subfraction profile and thereby prevent coronary artery disease. The fibric acid derivatives, which can reduce trigl yceride concentration by 25-45 % , improve the LDL subfraction profile but alter overall LDL cholesterol concentrations relatively little.' Conversely, 3-hydroxy-3-methyl-glutaryl co-enzyme A (HMG-CoA) reductase inhibitors (statins) do not appear to alter LDL profile but have a significant impact on LDL cholesterol concentration. The combination of a fibrate and a statin may result in more rapid LDL-receptormediated clearance (a statin action) of larger LDL sub fractions (a fibrate action)." However, this strategy carries an increased risk of side effects, particularly myalgia and rhabdomyolysis. Atorvastatin can reduce triglyceride and LDL cholesterol by up to 45 and 61%, respectively.? Atorvastatin may therefore offer an effective monotherapy to improve LDL profile with fewer side effects than a fibrate-statin combination.
We studied the effects of atorvastatin on the LDL subfraction profile in nine patients [mean (SD) age 48 (12) years, six men, three women] participating in a large, comparative efficacy trial. Patients were treated for 93 (25) days Correspondence: Dr Marlin J Landray. E-mail: m.j.landray@bham.ac.uk 240 [mean (SD)]. Following initial screening at which blood was taken for baseline fasting lipid profile (including LDL subfractions), patients were assigned between 10 and 80 mg atorvastatin [mean (SD) 56 (31) mg] on the basis of LDL cholesterol concentration and level of cardiovascular risk. Patients were seen every 12 weeks throughout the study and a further fasting blood sample was taken on completion of the study. The study was approved by the South Birmingham Local Research Ethics Committee.
Blood was taken into Vacutainer'" tubes (Becton Dickinson, Meylan, France). Serum was separated after centrifugation at 3000 g at 4°C for 15 min and stored at -80°C. Total cholesterol and triglyceride were measured by standard enzymatic techniques. High-density lipoprotein (HDL)-cholesterol was measured using the N-geneous direct enzymatic assay (Biostat, Stockport, UK). LDL-cholesterol concentration was calculated from the Friedewald formula.
LDL subfraction profile was measured by disc polyacrylamide electrophoresis (DPAGE).6 This technique allows separation of LDL into a number of subfraction bands, numbered 0 to 6, according to their relative mobility with respect to HDL. It is then possible to calculate an LDL score by determining the relative area under the curve of each band, multiplying by the band number and summing the results as follows:
Intra-and inter-assay coefficients of variation were 6 and 12%, respectively. Results may also be expressed as percentage (%) area under the curve for large (bands 0 and I), moderate (band 2) or small (bands 3-6) subfractions. By multiplying the percentage area under the curve by the overall LDL-cholesterol concentration, the concentration of cholesterol in each subfraction may be calculated. Treatment with atorvastatin was associated with significant reductions in triglyceride, total and LDL-cholesterol (see Table I ). The -37,5% -22,6% +1,2% -47,6% -23,2% -21·6% +36,7% -50% -100% -31,8% -69'6% -100% p.
All numbers are given as mean (SD). ·Paired t-test. HDL = high-density lipoprotein; LDL = low-density lipoprotein.
proportion of large LDL subfractions was significantly increased, with a reduction in the proportion of medium and small LDL subfractions. Although there was a significant reduction in overall LDL-cholesterol concentration (47'6%), the effect was much less marked in the large LDL subfraction-cholesterol (31'8%, not statistically significant) than in the medium (69'6%, P = 0'05) and small subfractions. These data suggest that not only does atorvastatin reduce the overall concentrations of triglyceride and LDL-cholesterol but that it is also able to improve the LDL subfraction profile with a shift towards the larger subfractions. The patients in this study did not have hypertriglyceridaemia (all < 3·2 mmol/L) and as a consequence the LDL subfractions were predominantly large. The ability of this study to reliably demonstrate alterations in the small subfractions (bands 3 to 6) is limited by their low prevalence at baseline. At follow-up, no small subfractions were detectable.
Previous studies with other statins have not demonstrated such an improvement in the LDL subfraction profile. We postulate that the reduction in triglyceride in response to atorvastatin results in less CETP-mediated neutral lipid exchange and consequently reduced formation of the moderate and small LDL subfractions. The large LDL subfractions may be removed by LDL receptors, a process again enhanced by atorvastatin.
The data presented come from a non-randomized, open-label, non-placebo controlled study of atorvastatin. Nonetheless, the results are of some interest and suggest there may be a greater cardioprotective impact if the LDL-lowering is combined with an improvement in subfraction profile. A large-scale, randomized controlled trial is required to confirm these results.
